The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Glypican 3: A Novel Marker in Testicular Germ Cell Tumors
Abstract
Glypican 3 (GPC3), a membrane-bound heparin sulfate proteoglycan, may play a role in promoting embryonic cell growth and differentiation. GPC3 is mutated in Simpson-Golabi-Behmel syndrome, characterized by tissue overgrowth and an increased risk of embryonal malignancies. Recently, GPC3 was reported to be one of the over-expressed genes in testicular yolk sac tumors by gene expression microarray analysis. However, the presence of the GPC3 protein in germ cell tumors has never been investigated. The purpose of the study was to investigate the GPC3 expression in various histologic components of testicular germ cell tumors using immunohistochemistry and to assess its possible utility as a diagnostic marker. Tumors from 71 patients were examined, including components of 42 seminomas, 37 embryonal carcinomas, 24 yolk sac tumors, 20 teratomas with mature elements, 16 teratomas with immature elements, and 7 choriocarcinomas. Cytoplasmic and membranous immunoreactivity was semiquantitatively evaluated. All yolk sac tumor (24/24) and choriocarcinoma (7/7) components were immunoreactive for GPC3, whereas only 38% of teratomas with immature elements and 8% of embryonal carcinomas expressed GPC3. There was no immunoreactivity in benign testicular tissue, intratubular germ cell neoplasia, seminomas (0/42), or teratomas with mature elements (0/20). We conclude that the oncofetal protein GPC3 is a novel immunohistochemical marker in testicular germ cell tumors with differential expression in defined histologic subtypes. Our findings suggest a possible role of GPC3 in tumor cell differentiation. Furthermore, GPC immunostaining may be useful in the pathologic diagnosis of nonseminomatous germ cell tumors, particularly yolk sac tumor, and choriocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma
Yamauchi, N., Watanabe, A., Hishinuma, M., Ohashi, K.-I., Midorikawa, Y., Morishita, Y., Niki, T., Shibahara, J., Mori, M., Makuuchi, M., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800436 · Cited by 338
Risk of tumorigenesis in overgrowth syndromes: a comprehensive review
Lapunzina, P. (2005) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30064 · Cited by 276 · cited 2×
“Although inactivating mutations are believed to cause SGB syndrome, approximately 10% of these patients acquire a malignancy, including neuroblastoma, gonadoblastoma, Wilms tumor, hepatoblastoma, or hepatocellular carcinoma.(20) Surprisingly, sporadically occurring forms of these neoplasms have increased GPC3 expressi…”
Background
Cited by
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., et al. (2025) · Nature · doi:10.1038/s41586-024-08261-8 · Cited by 289
Baumhoer, D., Tornillo, L., Stadlmann, S., Roncalli, M., Diamantis, E. K., & Terracciano, L. M. (2008) · American Journal of Clinical Pathology · doi:10.1309/hcqwpwd50xhd2dw6 · Cited by 262
Metadata
- Authors
- Zynger, D. L., Dimov, N. D., Luan, C., Tean Teh, B., & Yang, X. J.
- Venue
- American Journal of Surgical Pathology
- Published
- 2006-12
- Volume
- 30
- Issue
- 12
- Pages
- 1570-1575
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W1986826580
- Cited by
- 185
- References
- 2
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.